KNSA Stock Cash Flow Statements

Kiniksa Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Kiniksa Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30

cash flows from operating activities:
net income	17,832,000	8,539,000	-8,888,000	-12,693,000	-3,908,000	-17,704,000	25,237,000	-13,855,000	14,972,000	-12,270,000	4,461,000	224,093,000	-19,981,000	-25,210,000	-36,333,000	-30,544,000	-41,563,000	-49,484,000	-53,657,000	-43,836,000	-37,469,000	-26,419,000	-31,797,000	-27,058,000	-37,191,000	-65,821,000	-42,580,000	-24,406,000
adjustments to reconcile net income to net cash from operating activities
depreciation and amortization expense	358,000	345,000	400,000	399,000	430,000	466,000	540,000	603,000	602,000	596,000	602,000	493,000	651,000	656,000	668,000	658,000	717,000	312,000
share-based compensation expense	8,876,000	7,748,000	8,298,000	7,826,000	7,363,000	7,206,000	7,773,000	6,788,000	6,473,000	6,115,000	6,372,000	6,041,000	6,676,000	6,031,000	6,131,000	6,199,000	5,717,000	7,126,000	6,257,000	5,558,000	4,851,000	4,209,000	4,965,000	3,758,000	3,464,000	2,893,000	2,582,000	1,502,000
non-cash lease expense	924,000	835,000	767,000	754,000	836,000	779,000	737,000	707,000	769,000	841,000	788,000	772,000	746,000	735,000	736,000	702,000	600,000	593,000	639,000	158,000	303,000	300,000
net amortization of premiums and accretion of discounts on short-term investments
net gain on disposal of property and equipment
deferred income taxes	2,644,000	2,993,000	-3,163,000	-3,639,000	10,569,000	4,365,000	-25,709,000	10,288,000	-19,444,000	1,077,000	348,000							10,000	40,000	-51,000	5,410,000	-1,038,000	255,000	-2,021,000	-1,150,000	-240,000	-43,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	-6,868,000	-5,327,000	13,799,000	-6,992,000	-13,267,000	3,750,000	8,845,000	-13,987,000	709,000	-2,634,000	4,868,000	-1,305,000	-3,489,000	-3,932,000
accounts receivable	8,155,000	1,659,000	-16,836,000	-4,437,000	-4,456,000	5,271,000	-18,225,000	21,609,000	-17,226,000	5,236,000	-1,501,000	-3,351,000	21,632,000	-25,455,000	-686,000	-673,000
inventory	-26,112,000	4,295,000	2,316,000	6,178,000	-7,580,000	3,844,000	-5,539,000	-1,625,000	-533,000	-1,826,000	-6,978,000	5,295,000	-6,693,000	-9,548,000	1,931,000	775,000
other long-term assets	-70,000	2,045,000	-2,524,000	-10,000	-3,839,000	-3,362,000	1,406,000	0	-90,000	3,268,000	-265,000	1,000	163,000	2,755,000	-2,225,000	-780,000	-48,000	-231,000
accounts payable	6,930,000	62,000	-6,284,000	911,000	1,729,000	-2,662,000	7,234,000	364,000	-743,000	-6,508,000	6,430,000	-1,053,000	-861,000	1,515,000	250,000	-2,538,000	3,582,000	72,000	-3,265,000	1,524,000	-2,031,000	-1,197,000	-201,000	-2,841,000	1,680,000	-3,343,000	5,842,000
accrued expenses, accrued collaboration expenses and other current liabilities	13,098,000	-3,596,000	10,993,000	10,796,000
operating lease liabilities	-925,000	-852,000	-788,000	-877,000	-1,032,000	-1,287,000	-706,000	-741,000	-826,000	-988,000	-790,000	-781,000	-793,000	-643,000	-853,000	-837,000	-442,000	-421,000	-594,000	-272,000	-420,000	-413,000	-348,000	-314,000	-309,000	-293,000
deferred revenue			20,000,000	-1,000	-155,000	-294,000	-2,175,000	-2,244,000	-1,978,000	6,658,000	-14,290,000	14,290,000	0	12,000,000
other long-term liabilities	4,126,000	3,313,000	-139,000	36,000	35,000	33,000	-87,000	30,000	31,000	45,000	19,000	1,560,000	-11,000	1,000	-615,000	-257,000	333,000	4,000	-152,000	623,000	-48,000	55,000	-617,000	0	434,000	509,000
net cash from operating activities	28,090,000	22,324,000	18,770,000	-2,236,000	5,168,000	3,987,000	4,325,000	16,986,000	-3,743,000	-4,267,000			-7,824,000	-36,846,000	-18,884,000	-28,509,000	-38,783,000	-40,122,000	-41,191,000	-34,321,000	-29,224,000	-31,796,000	-24,170,000	-29,267,000	-41,676,000	-63,256,000	-27,638,000
capex	139,000	-65,000	-193,000	23,000	76,000	18,000	-56,000	-16,000	-34,000	-24,000			0	0	-251,000	-51,000	-59,000	-54,000	-55,000	-5,000	0	-223,000	-1,996,000	-440,000	794,000	-1,561,000	-4,016,000
free cash flows	28,229,000	22,259,000	18,577,000	-2,213,000	5,244,000	4,005,000	4,269,000	16,970,000	-3,777,000	-4,291,000			-7,824,000	-36,846,000	-19,135,000	-28,560,000	-38,842,000	-40,176,000	-41,246,000	-34,326,000	-29,224,000	-32,019,000	-26,166,000	-29,707,000	-40,882,000	-64,817,000	-31,654,000
cash flows from investing activities:
proceeds from sale of property and equipment			0	0							10,000	-10,000
purchases of property and equipment	-165,000	-99,000	-193,000	0	0	-84,000	-56,000	-16,000	-34,000	-24,000	32,000	-22,000			-251,000	-51,000	-59,000	-54,000	-55,000	-5,000	0	-223,000	-1,996,000	-440,000	794,000	-1,561,000	-4,016,000
purchases of short-term investments	-34,323,000	-95,470,000	-21,994,000	-54,481,000	-89,263,000	-36,276,000	-60,817,000	-53,088,000	-38,132,000	-52,896,000	-62,802,000	-17,328,000	-25,511,000	-30,223,000	-59,790,000	0	-23,098,000	-74,362,000	-86,052,000	-210,205,000	-107,767,000	-26,187,000	-82,638,000	-132,647,000	-91,681,000	-181,807,000	-109,424,000
proceeds from the maturities of short-term investments	30,605,000	44,028,000	87,480,000	48,133,000	42,441,000	61,884,000	45,979,000	40,827,000	73,700,000	15,000,000	20,100,000	36,400,000	63,800,000	7,500,000	10,000,000	47,900,000	109,150,000	139,250,000	154,750,000	60,550,000	76,550,000	115,200,000	86,550,000	148,300,000	132,250,000	174,090,000	143,100,000
net cash from investing activities	-3,883,000	-51,541,000	65,293,000	-6,348,000	-46,797,000	25,524,000	-14,894,000			-37,920,000	-42,660,000	19,040,000	38,265,000	-22,723,000	-50,041,000	47,849,000	85,993,000	44,834,000	68,643,000	-149,660,000	-31,217,000	88,790,000	1,916,000	15,213,000	41,363,000	-9,278,000	29,660,000
cash flows from financing activities:
proceeds from issuance of class a ordinary shares under incentive award plans and employee share purchase plan	12,745,000	3,180,000	2,720,000	9,401,000
payments in connection with ordinary shares tendered for employee tax obligations	-2,047,000	-412,000
net cash from financing activities	10,698,000	2,768,000	2,142,000	6,689,000	-178,000	3,613,000	695,000	552,000	158,000	90,000	1,190,000	361,000	542,000	423,000	1,212,000	2,680,000	887,000	1,106,000	712,000	146,399,000	77,561,000	2,414,000	373,000	53,000	494,000	83,187,000	291,000	-762,000
net increase in cash and cash equivalents	34,905,000	-26,449,000				33,124,000
cash and cash equivalents at beginning of period	0	183,581,000	0	0	0	107,954,000		0	0	122,715,000
cash and cash equivalents at end of period	34,905,000	157,132,000	86,205,000	-1,895,000	-41,807,000	141,078,000		5,261,000	31,949,000	80,618,000

supplemental information:
cash paid for income taxes	1,000	3,008,000	1,262,000	-769,000			-1,312,000	201,000	3,520,000	3,196,000	6,081,000	1,315,000			420,000	5,000			0	200,000			-3,000	700,000			38,000	197,000
supplemental disclosure of non-cash investing and financing activities:
change in right-of-use asset as a result of new, modified, and terminated leases	775,000	912,000	48,000	70,000	291,000	1,172,000	0	184,000
additions to property and equipment included in accounts payable and accrued expenses and other liabilities	304,000	34,000		23,000	76,000	102,000
amortization of premiums and accretion of discounts on short-term investments		255,000		-487,000	-188,000	297,000		1,441,000	-1,152,000	-1,061,000		-119,000	76,000	164,000		14,000	193,000	410,000
net income on disposal of property and equipment		10,000
adjustments to reconcile net income to net cash from operating activities:
amortization (accretion) of discounts on short-term investments
gain on disposal of property and equipment			0	0
loss on disposal of property and equipment			0	0			4,000	0	0	175,000	10,000	-11,000											-2,000				0	0
contract asset							0	0	0	7,656,000
payments in connection with ordinary stock tendered for employee tax obligations			-578,000	-2,712,000
additions to property and equipment included in accrued expenses and other liabilities
net decrease in cash and cash equivalents				-1,895,000				5,261,000	31,949,000	-42,097,000
accrued expenses and other current liabilities						3,285,000	5,286,000	7,608,000	14,693,000	-10,647,000	-3,791,000	1,971,000	-5,974,000	4,085,000
proceeds from issuance of class a common shares under incentive award plans and employee share purchase plan						3,994,000	957,000	1,657,000	577,000	510,000	1,290,000	569,000	566,000	992,000	1,212,000	2,680,000
payments in connection with common stock tendered for employee tax obligations						-381,000	-262,000	-1,105,000	-419,000	-420,000	-100,000	-208,000	-24,000	-569,000
intangible assets acquired
net increase in cash, cash equivalents and restricted cash											-53,046,000	81,454,000	30,983,000	-59,146,000	-67,713,000	22,020,000	48,097,000	5,818,000	28,164,000	-37,582,000	17,120,000	59,408,000
cash, cash equivalents and restricted cash at beginning of period											0	0	0	122,470,000	0	0	0	114,248,000	0	0	0	47,138,000
cash, cash equivalents and restricted cash at end of period											-53,046,000	81,454,000	30,983,000	63,324,000	-67,713,000	22,020,000	48,097,000	120,066,000	28,164,000	-37,582,000	17,120,000	106,546,000
net cash provided (used) in investing activities
right-of-use asset obtained in exchange for operating lease obligation										684,000	0				157,000
proceeds from issuance of class a common shares from follow-on offerings, net of underwriting discounts and commissions, inclusive of the over-allotment option exercise																			0
proceeds from issuance of class a1 common shares from private placements, net of placement agent fees																			0
payments of offering costs																			-160,000	-407,000			0	0	-18,000	-100,000
net cash provided (used) in operating activities
intangible asset acquired																0	0	-20,000,000
class a common shares issued as consideration for primatope, including milestone payments
accrued milestones																							-150,000	150,000	-13,000,000	-2,000,000
property and equipment included in accrued expenses and accounts payable																							-149,000	118,000	216,000	37,000	234,000
prepaid expenses and other assets																1,230,000	-604,000	408,000		-1,925,000	-3,245,000	-598,000					-764,000
accrued expenses and other liabilities																-2,458,000	1,674,000	1,079,000		3,177,000	2,915,000	-7,061,000	1,953,000	-35,000	3,096,000	-376,000
proceeds from issuance of class a common shares from follow-on offering, net of underwriting discounts and commissions, inclusive of the over-allotment option exercise
proceeds from issuance of class a1 common shares from private placement, net of placement fees
deferred offering costs included in accrued expenses and accounts payable																				-181,000						19,000	393,000	-845,000
proceeds from issuance of class a common shares under incentive award plans																		1,106,000
depreciation expense																			567,000	649,000	595,000	594,000	566,000	523,000	508,000	471,000	254,000	12,000
other
prepaid expenses and other short-term assets
accrued expenses and other short-term liabilities
proceeds from issuance of series c convertible preferred shares, net of issuance costs																											0	0
proceeds from issuance of class a common shares upon completion of initial public offering, net of underwriting discounts and commissions, inclusive of the over-allotment option exercise
class a common shares issued or to be issued as consideration for primatope, including milestone payments																							0	0
accretion of discounts on short-term investments																				74,000	-85,000	-228,000	-457,000	-989,000	-1,209,000	-846,000	-753,000
proceeds from exercise of options and employee share purchase plan																				331,000	2,936,000	2,414,000	373,000	53,000	512,000	181,000
proceeds from issuance of class a1 common shares from private placement, net of placement agent fees
proceeds from issuance of class a common shares from follow-on offering, net of underwriting commissions and discounts, inclusive of the over-allotment option exercise																							0	0	0	48,595,000
proceeds from issuance of class a1 common shares from private placement, net of underwriting commissions and discounts																							0	0	0	34,511,000
proceeds from issuance of class a common shares upon completion of initial public offering, net of underwriting commissions and discounts, inclusive of the over-allotment option exercise
net increase in cash and cash equivalents and restricted cash																							-21,881,000	-14,001,000	181,000	10,653,000	2,313,000	-216,118,000
cash, cash equivalents, and restricted cash at beginning of period
cash, cash equivalents, and restricted cash at end of period
non-cash rent expense																											-23,000	50,000
prepaid expenses, right-of-use assets and other assets																								-463,000	201,000	-1,210,000
cash and cash equivalents and restricted cash at beginning of period																								0	0	72,186,000	0	0
cash and cash equivalents and restricted cash at end of period																								-14,001,000	181,000	82,839,000	2,313,000	-216,118,000
class a common shares issued or to be issued as consideration for primatope																										7,000,000
proceeds from issuance of series b convertible preferred shares, net of issuance costs
accrued expenses																												833,000
proceeds from issuance of class a common shares upon completion of initial public offering, net of underwriting commissions and discounts																												0
payments of deferred offering costs
proceeds from exercise of options																												59,000

We provide you with 20 years of cash flow statements for Kiniksa Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Kiniksa Pharmaceuticals stock. Explore the full financial landscape of Kiniksa Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Kiniksa Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.